Comparison of sertaconazole, eberconazole and miconazole creams in treatment of ringworm infection.
- Conditions
- Health Condition 1: null- Tinea (dermatophytosis) excluding hair and nails
- Registration Number
- CTRI/2018/04/012971
- Lead Sponsor
- Department of Pharmacology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 206
1. Patients suffering from dermatophyte infection in the form of localized tinea lesions such as tinea corporis and tinea cruris.
2. Willing to provide written informed consent.
1. Female patients who are pregnant or breast feeding.
2. Patients with disseminated tinea infection.
Patients with uncontrolled diabetes mellitus or severely immunocompromising disorders like HIV/AIDS.
3. Patients with serious disease of vital organs like heart, lungs, liver, kidney or bone marrow.
4. Patients suffering from alcoholism, other substance abuse disorders or active psychiatric disorders.
5. Patients with history of hypersensitivity to systemic or topical formulations of azole antifungals including miconazole, sertaconazole or eberconazole.
6. Participation in another clinical trial within last 30 days.
7. Any other condition, which in the opinion of the principal investigator, will prevent the subject from complying with visit schedules and instructions.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical cure at 4 weeks â?? implying resolution of the lesion and associated symptoms.Timepoint: Baseline 2 weeks 4 weeks
- Secondary Outcome Measures
Name Time Method Changes in Total Symptom Score (TSS) based on erythema, scaling, and pruritus scores.Timepoint: Baseline 2 weeks 4 weeks;Clinical cure at 2 weeks.Timepoint: 2 weeks;Overall response at 4 weeks based on 6 point global response scale.Timepoint: 4 weeks